avid200
Small moleculeexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2019 (NCT03831438)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Transforming growth factor beta-1ANTAGONIST
TGFB1 antagonist
- Transforming growth factor beta-3ANTAGONIST
TGFB3 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03895112 | Phase 1 | Feb 15, 2019 | Forbius, Icahn School of Medicine at Mount Sinai, Myeloproliferative Neoplasm Research Consortium (MPN-RC), National Cancer Institute (NCI), University of Texas, San Antonio |
| NCT03834662 | Phase 1 | Jan 7, 2019 | Forbius |
| NCT03831438 | Phase 1 | Jan 1, 2019 | Forbius, University of Pittsburgh |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Forbius | For profit | 3 | 2 | 1 | 2019 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Myeloproliferative Neoplasm Research Consortium (MPN-RC) | Academic/Hospital | 1 | 0 | 1 | 2019 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2019 |
| University of Pittsburgh | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Texas, San Antonio | Academic/Hospital | 1 | 0 | 1 | 2019 |
6 organizations
Page 1 / 1